Gonadotrophin-releasing hormone agonist and laparoscopic myomectomy.
The indications for operative laparoscopy have expanded greatly over the past decades, as its many advantages over laparotomy have been recognized. We report our techniques and short-term results concerning myomectomy by laparoscopy. From January 1, 1990 to October 1, 1991, 147 intraperitoneal myomectomies were performed in 70 patients: 46 of 70 were treated preoperatively with a depot gonadotrophin-releasing hormone agonist. No complications were observed. In selected cases, with the advantages of laparoscopic surgery, laparoscopic myomectomy appears to be a safe technique.
Dubuisson
J B
JB
Clinique Universitaire Port-Royal, Paris, France.
Lecuru
F
F
Foulot
H
H
Mandelbrot
L
L
Bouquet de la Jolinière
J
J
Aubriot
F X
FX
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D010535:Laparoscopy; D007889:Leiomyoma / Q000188:drug therapy / Q000601:surgery*; D016729:Leuprolide / Q000627:therapeutic use; D011292:Premedication; D013536:Suture Techniques; D017329:Triptorelin Pamoate; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000601:surgery*
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide